Results 91 to 100 of about 456,696 (362)

Lower limb function and quality of life after ILP for soft-tissue sarcoma

open access: yesWorld Journal of Surgical Oncology, 2017
Background Isolated limb perfusion with TNF-alpha and melphalan (TM-ILP) in combination with complete tumor resection is an effective treatment option for non-resectable soft-tissue sarcoma of the extremities, with limb salvage rates greater than 80 ...
Lars Erik Podleska   +5 more
doaj   +1 more source

BMN673 sensitizes rhabdomyosarcoma tumors to irradiation in vivo [PDF]

open access: yes, 2020
Bone and soft tissue sarcomas are mesenchymal tumors that occur rarely in adults, representing only 1% of total malignancies, but comprise up to 13% of malignant tumors in children.1 Rhabdomyosarcoma, a soft tissue sarcoma that commonly affects children,
Jacob, Connor
core  

The reverse protraction factor in the induction of bone sarcomas in radium-224 patients [PDF]

open access: yes, 1990
More than 50 bone sarcomas have occurred among a collective of about 800 patients who had been injected in Germany after World War II with large activities of radium-224 for the intended treatment of bone tuberculosis and ankylosing spondylitis.^In an ...
Chmelevsky, D.   +3 more
core   +1 more source

Revisiting CDKN2A dysregulation in Ewing sarcoma

open access: yesMolecular Oncology, EarlyView.
We revisit CDKN2A to investigate its role as a potential prognostic biomarker in Ewing sarcoma using data from pre‐clinical models as well as clinical samples. Ewing sarcoma (EwS) is a rare and aggressive malignancy, which frequently affects children.
Anjali Paragji   +8 more
wiley   +1 more source

Retrospective quality of life study in patients with retroperitoneal sarcoma in an Asian population

open access: yesHealth and Quality of Life Outcomes, 2020
Background Retroperitoneal sarcoma represents 15% of sarcomas. The mainstay of treatment is surgery where a majority of patients require multi-visceral resections that may significantly impact their quality of life (QOL) following surgery.
Hui Jun Lim   +8 more
doaj   +1 more source

Pre-B-cell acute lymphoblastic leukemia with bulk extramedullary disease and chromosome 22 (EWSR1) rearrangement masquerading as Ewing sarcoma [PDF]

open access: yes, 2010
We report a 2-year-old female with a subcutaneous tumor who was initially misdiagnosed as suffering from Ewing sarcoma with a positive EWSR1 rearrangement and EWS/FLI1 transcript.
Jakovljević, Gordana   +6 more
core   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

open access: yesMolecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau   +11 more
wiley   +1 more source

Nanodiamond as a vector for siRNA delivery to Ewing sarcoma cells [PDF]

open access: yesarXiv, 2011
We investigated the ability of diamond nanoparticles (nanodiamonds, NDs) to deliver small interfering RNA (siRNA) in Ewing sarcoma cells, in the perspective of in vivo anti-cancer nucleic acid drug delivery. siRNA was adsorbed onto NDs previously coated with cationic polymer. Cell uptake of NDs has been demonstrated by taking advantage of NDs intrinsic
arxiv  

Association of endometrioid ovarian carcinoma arising from endometriosis, endometrioid endometrial carcinoma, and high-grade undifferentiated endometrial sarcoma. a case report [PDF]

open access: yes, 2017
Endometriosis is a chronic disease that affects women of reproductive age. Malignant transformation in endometriosis is considered to be an unusual event, only occurring in 0.7-0.1% of cases.
Caserta, D.   +3 more
core   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy